Skip to content

Impact of Prokinetic Use After Emergency Intestinal Anastomosis on Postoperative Clinical Outcomes

Impact of Prokinetic Use After Emergency Intestinal Anastomosis on Short and long_term Clinical Outcome

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05290753
Enrollment
15
Registered
2022-03-22
Start date
2022-01-01
Completion date
2022-07-01
Last updated
2022-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prokinetic Use After Emergency Intestinal Anastomosis

Brief summary

Prokinetic drugs used to accelerate healing of intestinal anastomosis of urgent cases which not prepared preoperative by increase intestinal motility and gastric emptying and decrease postoperative adhesions They are many types of prokinetics as cholinergic agonists, dopamine antagonist, serotonergic agonists and macrolides Agents of prokinetics administered immediately post operation and at the time of hospitalization

Detailed description

By evaluation the effect of prokinetic use versus non use after emergency intestinal intestinal anastomosis on short and long term clinical outcome It will be prospective cohort study which conducted in sohag university hospital Study will include patients presented with urgent anastomosis Inclusion criteria: all adults underwent emergency intestinal anastomosis Exclusion criteria: pediatrics, patients with comorbidities and patients with electively resection and anastomosis. Primary goals are to detect effect of prokinetics on incidence of leakage rate Secondary outcomes include early bowel opening, enteral feeding, post operative pain, wound infection and adhesion formation rate.

Interventions

DRUGProkinetic Motility Agents as primpiram and gastreg

Prospective cohort study to evaluate the effect of pro kinetic use in emergency intestinal anastomosis

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* all adult patients

Exclusion criteria

* pediatrics * patients associated with comorbidities * patients with electively resection and anastomosis

Design outcomes

Primary

MeasureTime frameDescription
Leakage rate5 days postoperativeFecal fistula

Secondary

MeasureTime frameDescription
Early bowel opening3 days postoperativeDuration taken to patient to pass feces and flatus

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026